THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 2 DATA

In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually condition progression or maybe the individuals are unable to tolerate the study drugs.and afterwards market H3K27Ac at this area. Chromatin hyperacetylation could increa